医学
伊瓦卡夫托
四分位间距
囊性纤维化
人口
内科学
弹性成像
胃肠病学
核医学
泌尿科
超声波
放射科
囊性纤维化跨膜传导调节器
环境卫生
作者
Konstantinos Douros,Aikaterini Kanavaki,Ino Kanavaki,P.S. Zoumpoulis,Maria Moustaki,Ioanna Loukou
标识
DOI:10.2174/1574886317666220513105114
摘要
Background: Lumacaftor/Ivacaftor (LUM/IVA) is an approved combination therapy for cystic fibrosis (CF) patients homozygous for F508del. Objective: This study aimed to detect changes in liver stiffness measurement (LSM) in patients under this treatment. Methods: The study population consisted of CF patients homozygous for F508del, 6 to 11 years old, who had been treated for six months with LUM/IVA. Shear wave elastography (SWE) was performed in all of them, before and 6 months after the commencement of treatment. Results: Thirty-one patients were included in the study. LSM values after treatment were significantly higher than the values before treatment (medians and interquartile ranges of LSM values before and after treatment: 5.6, 5.3-6.3 kPa and, 6.4, 6.0-7.6 kPa, respectively, p<0.001). Conclusion: SWE can detect early changes in LSM in some CF patients treated with LUM/IVA.
科研通智能强力驱动
Strongly Powered by AbleSci AI